Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

WINDLAS BIOTECH LTD.

NSE : WINDLASBSE : 543329ISIN CODE : INE0H5O01029Industry : Pharmaceuticals & DrugsHouse : Private

BSE544.00-8.2 (-1.48 %)

PREV CLOSE ( ) 552.20

OPEN PRICE ( ) 554.40

BID PRICE (QTY) 546.75 (5)

OFFER PRICE (QTY) 548.20 (28)

VOLUME 4356

TODAY'S LOW / HIGH ( )540.10 556.60

52 WK LOW / HIGH ( )250.85 590

NSE546.75-3.9 (-0.71 %)

PREV CLOSE( ) 550.65

OPEN PRICE ( ) 555.00

BID PRICE (QTY) 546.85 (1)

OFFER PRICE (QTY) 547.50 (130)

VOLUME 33110

TODAY'S LOW / HIGH( ) 541.10 557.80

52 WK LOW / HIGH ( )251 590.85

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 19-02 2001

Management Info

Vivek Dhariwal - Chairman Hitesh Windlass - Managing Director

Registered Office

Address 40 / 1,Mohabewala Industrial Area,,
Dehradun,
Uttarakhand-248110

Phone 0135-6608000-30

Email grievance@windlasbiotech.com

Website www.windlasbiotech.com

Registrars Details

Link Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

29Apr Windlas Biotech informs about analyst
Pursuant to the relevant provisions of SEBI (Listing Obligations and Dis..

03Apr Windlas Biotech surges on commissionin
Windlas Biotech is currently trading at Rs. 562.85, up by 12.90 points o..

02Apr Windlas Biotech informs about press re
Windlas Biotech has informed that it attached press release on ‘Windlas..

02Apr Windlas Biotech commissions injectable
Windlas Biotech has commissioned its state-of-the-art injectable facilit..

20Feb Windlas Biotech informs about analyst
Pursuant to the relevant provisions of SEBI (Listing Obligations and Dis..

Financials

Rs. in Millions

	QTR Dec 23	ANNUAL 23
Net Profit	150.98	426.44
Gross Profit	198.07	570.57
Operating Profit	235.01	702.07
Net Sales	1622.13	5130.83

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Ajanta Pharma (BSE) 2389.00 (6.98%)	M.Cap ( in Cr)30330.17
Alkem Laboratories (BSE) 4914.70 (2.68%)	M.Cap ( in Cr)58174.95
Astrazeneca Pharma I (BSE) 5440.00 (1.99%)	M.Cap ( in Cr)13542.13
Dr. Reddy's Lab (BSE) 6371.10 (1.32%)	M.Cap ( in Cr)106880.46
Torrent Pharma (BSE) 2739.70 (2.46%)	M.Cap ( in Cr)92420.99

Shareholding Pattern

	PROMOTERS	62.82%
	NON-INSTITUTION	24.19%
	MUTUAL FUNDS/UTI	10.37%
	FI/BANKS/INSURANCE	0%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
UTI Healthcare Fund...	1.16
ICICI Pru Pharma He...	1.16
ICICI Pru Smallcap ...	0.77

Risk Disclosures on Derivatives

Smart Quotes

WINDLAS BIOTECH LTD.